MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Short-term Debt · Q3 FY2026 · quarter ended Sep 2026

Short-term debt remains negative

Q3 FY2026 short-term debt was $0, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Short-term debt amounts to 0.0% of total assets for MBX, versus a peer median of 0.0%.
MBX Competitors
Short-term Debt for MBX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ASNDAscendis Pharma A/SSep 2026€70.15M EUR-85.5%+5.6%2.9%
XERSXeris Biopharma Holdings, Inc.Mar 2026$6.27M USD-47.6%—1.6%
KLRAKailera Therapeutics, Inc.Jun 2026$1.05M USD——0.1%
ORMPOramed Pharmaceuticals Inc.Mar 2026$268K USD——0.1%
MBXMBX Biosciences, Inc. Common StockSep 2026$0 USD——0.0%
RYTMRhythm Pharmaceuticals, Inc.Sep 2026$0 USD——0.0%
VKTXViking Therapeutics, Inc.Jun 2026$0 USD——0.0%
ALTAltimmune, Inc.Mar 2026$0 USD——0.0%
BMEABiomea Fusion, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding MBX) —-66.5%+5.6%0.0%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents24.21M30.52M49.35M75.29M
Short-term Investments18.25M50.15M212.8M298.42M
Net Receivables142K208K682K2.12M
Inventory0000
Other Current Assets84K133K803K861K
Total Current Assets44.21M83.47M267.29M381.54M
Property, Plant & Equipment (Net)842K665K1.2M3.22M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets42K50K50K383K
Total Non-current Assets884K715K1.25M3.61M
Total Assets45.1M84.18M268.54M385.14M
Account Payables976K1.39M5.34M2.98M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities1.13M1.37M2.32M4.32M
Total Current Liabilities3.43M3.93M11.05M15.5M
Long-term Debt000424K
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities83.95M152.55M42K2K
Total Non-current Liabilities84.27M152.72M42K426K
Total Liabilities87.7M156.65M11.09M15.92M
Common Stock1K1K5K6K
Retained Earnings(43.02M)(75.58M)(137.51M)(224.48M)
Accumulated OCI3K60K55K286K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(42.61M)(72.47M)257.44M369.22M
Total Debt461K324K171K596K
Net Debt(23.75M)(30.2M)(49.18M)(74.69M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.